Zymergen

Zymergen
Name	Zymergen
Type	Private
Founded	2013
Founders	Josh Hoffman; Zach Serber; Joshua Hoffman; Christina Agapakis
Headquarters	Emeryville, California
Industry	Biotechnology
Products	Bioproducts; enzymes; specialty chemicals

Zymergen Zymergen is a biotechnology company founded in 2013 that developed genomics-driven processes for engineering microbes to produce industrial chemicals, materials, and enzymes. The company combined automated laboratory platforms, machine learning, and high-throughput screening to design microbial strains for commercial manufacturing. Zymergen attracted attention for rapid scale-up efforts, strategic partnerships, and a controversial public offering in the late 2010s and early 2020s.

History

Zymergen was co-founded in 2013 by Josh Hoffman, Zach Serber, and Christina Agapakis with early involvement from venture capital firms like SoftBank Group, Founders Fund, GV (company), and Data Collective. Early milestones included technology development in synthetic biology laboratories near Berkeley, California and operational expansion to an automated "biofactory" reminiscent of facilities associated with Genentech, Amgen, and Ginkgo Bioworks. The company announced partnerships and pilot programs with corporations such as BASF, Sumitomo Chemical, and Decathlon while navigating a competitive landscape including Amyris, Twist Bioscience, Codexis, and Bluebird Bio. Zymergen pursued an initial public offering amid a climate influenced by listings from Moderna, Illumina, and 23andMe before encountering setbacks tied to financial disclosures and auditing overseen by firms including PricewaterhouseCoopers.

Technology and Platform

Zymergen's platform integrated laboratory automation inspired by instruments from Tecan, Hamilton Company, and concepts from synthetic biology centers like the J. Craig Venter Institute and Addgene. The company used high-throughput strain engineering and data pipelines leveraging machine learning approaches related to research at Google DeepMind, OpenAI, and academic labs at Massachusetts Institute of Technology, Harvard University, and Stanford University. Analytical methods drew upon techniques common to Illumina sequencing, Thermo Fisher Scientific mass spectrometry workflows, and metabolomics developed at Lawrence Berkeley National Laboratory. For design-build-test cycles Zymergen referenced methods similar to those used by Craig Venter-era genome engineering and computational models from groups like Carnegie Mellon University and University of California, Berkeley.

Products and Applications

Zymergen focused on bio-derived materials and specialty chemicals with potential applications in sectors served by Dow Chemical Company, DuPont, Procter & Gamble, and Unilever. Product lines included engineered enzymes relevant to industries represented by BASF SE and Clariant, bio-based monomers comparable to materials historically produced by ExxonMobil Chemical and Chevron Phillips Chemical Company, and additives for electronics manufacturing used by firms such as Sony Corporation and Samsung Electronics. Pilot products were marketed toward customers in agriculture-adjacent supply chains connected to Bayer AG and Corteva, as well as partners in textiles aligning with brands like H&M and Nike, Inc..

Business Model and Funding

Zymergen operated on a hybrid model combining fee-for-service strain development, licensing, and eventual product sales similar to business approaches by Ginkgo Bioworks and Amyris. Funding rounds involved venture investors including SoftBank Vision Fund, Temasek Holdings, and DCVC (Data Collective. The company's financial trajectory intersected with public market activity alongside companies such as Peloton Interactive, WeWork, and Dropbox during a period of heightened scrutiny of biotech valuations. Strategic decisions about manufacturing scaled with contract manufacturers reminiscent of Corbion and Lonza and procurement strategies seen at industrial players like 3M and BASF.

Controversies and Legal Issues

Zymergen faced controversy following disclosures about revenue recognition, audit adjustments, and workforce reductions that drew comparisons to high-profile corporate governance issues at Theranos, WeWork, and Luckin Coffee. Litigation and shareholder actions referenced practices scrutinized in cases involving Enron-era regulatory reforms and audits by firms linked to Big Four accounting firms such as PricewaterhouseCoopers and KPMG. Public scrutiny involved oversight from regulatory bodies and commentary from analysts who track listings similar to Nasdaq-traded biotechs. Employment and labor discussions at Zymergen echoed disputes seen at biotechnology workplaces including Vertex Pharmaceuticals and Genzyme.

Partnerships and Collaborations

Zymergen established collaborations with multinational corporations and research institutions such as BASF SE, Sumitomo Chemical, Mitsui & Co., and academic partners at University of California, Berkeley, Massachusetts Institute of Technology, and University of California, San Francisco. Commercial relationships paralleled partnerships between Ginkgo Bioworks and Bayer, Amyris and TotalEnergies, and joint development models used by ExxonMobil with synthetic biology startups. Corporate alliances drove pilot-scale manufacturing with contract development and manufacturing organizations reminiscent of Lonza, Patheon, and Catalent.

Category:Biotechnology companies Category:Companies established in 2013